

chain nodes :

15 19

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14

chain bonds :

7-15 8-19 11-15

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-14 11-12  
12-13 13-14

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 7-15 8-9 8-19 10-11  
10-14 11-12 11-15 12-13 13-14

G1:C,N

G2:O,S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom  
10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 19:Atom

09/191,199

=> d his

(FILE 'HOME' ENTERED AT 13:13:27 ON 15 OCT 2001)

FILE 'REGISTRY' ENTERED AT 13:14:11 ON 15 OCT 2001

L1 STRUCTURE UPLOADED

L2 QUE L1

L3 46469 S NC4-NC5/ES

L4 28 S L2 SUB=L3 FUL


FILE 'CAPLUS' ENTERED AT 13:16:26 ON 15 OCT 2001

L5 4 S L4

=> d l2

L2 HAS NO ANSWERS

L1 STR



G1 C,N

G2 O,S,N

Structure attributes must be viewed using STN Express query preparation.


L2 QUE ABB=ON PLU=ON L1

=> d bib abs hitstr 15 1-4


09/191,199

L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2001 ACS  
AN 2001:661426 CAPLUS  
DN 135:226880  
TI Synthesis of Pyrolyllactone-indolinone derivatives as kinase inhibitors  
IN Tang, Peng Cho; Miller, Todd A.; Li, Xiaoyuan; Zhang, Ruofei; Cui,  
Jingrong; Huang, Ping; Wei, Chung Chen  
PA Sugen, Inc., USA  
SO PCT Int. Appl., 148 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001064681	A2	20010907	WO 2001-US6214	20010228
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2000-185536	P	20000228		
GI					



I



II


AB Title compds. I [R1 = H, alkyl, (hetero)arom. ring, (hetero)aliph. ring, etc.; R2-5 = H, alkyl, (hetero)arom. ring, (hetero)aliph. ring; A, B, D, E = C or N provided that one or two = N and provided that when A, B, D or E = N, no R1 is attached to A, B, D or E; m = 2 - 4; q = 1 - 4] were prepd. Examples include data for over 50 compds. synthesized and over 20 bioassays (data for 4 bioassays provided). For instance, tosylmethyl isocyanide was added to 5,6-dihydro-2H-pyran-2-one (DBU, THF, 0.degree.C, room temp., 2 h.) to give 6,7-dihydro-2H-pyrano[3,4-c]pyrrol-4-one. This intermediate was formylated in the 1-position (DMF, POCl3, DCM, room temp., 1 h.) followed by condensation of the 1-formyl deriv. with 2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid N-Me amide to yield II. II had IC50 = 0.005 mM for cdk2/cyclin A and IC50 = 6.64 mM for GST-Flk1. Compds. II are used to treat cancer, e.g., squamous cell carcinoma, astrocytoma, Kaposi's sarcoma, etc.

IT 358733-07-0P 358733-08-1P 358733-09-2P  
358733-10-5P 358733-11-6P 358733-12-7P  
358733-13-8P 358733-14-9P 358733-15-0P  
358733-16-1P 358733-17-2P 358733-18-3P  
358733-19-4P 358733-20-7P 358733-21-8P  
358733-23-0P 358733-24-1P 358733-25-2P  
358733-26-3P 358733-27-4P 358733-28-5P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug; synthesis of Pyrolyllactone-indolinone derivs. as kinase inhibitors)


RN 358733-07-0 CAPLUS

CN 4H-Pyrrolo[3,4-c]pyridin-4-one, 1-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 358733-08-1 CAPLUS


CN 4H-Pyrrolo[3,4-c]pyridin-4-one, 1-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 358733-09-2 CAPLUS


CN 4H-Pyrrolo[3,4-c]pyridin-4-one, 1-[(6-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)

09/191,199




RN 358733-10-5 CAPLUS

CN 4H-Pyrrolo[3,4-c]pyridin-4-one, 1-[(6-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 358733-11-6 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N,N-dimethyl-2-oxo-3-[(4,5,6,7-tetrahydro-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]- (9CI) (CA INDEX NAME)



RN 358733-12-7 CAPLUS


CN 1H-Indole-5-carboxamide, 2,3-dihydro-N,N-dimethyl-2-oxo-3-[(4,5,6,7-tetrahydro-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]- (9CI) (CA INDEX NAME)



RN 358733-13-8 CAPLUS


CN Pyrrolidine, 1-[[2,3-dihydro-2-oxo-3-[(4,5,6,7-tetrahydro-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]-1H-indol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)

09/191,199




RN 358733-14-9 CAPLUS

CN Morpholine, 4-[[2,3-dihydro-2-oxo-3-[(4,5,6,7-tetrahydro-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]-1H-indol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 358733-15-0 CAPLUS

CN 4H-Pyrrolo[3,4-c]pyridin-4-one, 1-[[1,2-dihydro-4-(2-hydroxyethyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 358733-16-1 CAPLUS


CN 4H-Pyrrolo[3,4-c]pyridin-4-one, 1-[(1,2-dihydro-5-methoxy-2-oxo-3H-indol-3-ylidene)methyl]-2,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 358733-17-2 CAPLUS


CN 4H-Pyrrolo[3,4-c]pyridin-4-one, 1-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)

09/191,199




RN 358733-18-3 CAPLUS

CN 4H-Pyrrolo[3,4-c]pyridin-4-one, 1-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 358733-19-4 CAPLUS

CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-[(4,5,6,7-tetrahydro-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]- (9CI) (CA INDEX NAME)




RN 358733-20-7 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-[(4,5,6,7-tetrahydro-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]- (9CI) (CA INDEX NAME)




RN 358733-21-8 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(4,5,6,7-tetrahydro-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]- (9CI) (CA INDEX NAME)




RN 358733-23-0 CAPLUS

CN 4H-Pyrrolo[3,4-c]pyridin-4-one, 1-[[1,2-dihydro-4-(2-hydroxyethyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,5,6,7-tetrahydro-5-methyl- (9CI) (CA INDEX NAME)




RN 358733-24-1 CAPLUS

CN 4H-Pyrrolo[3,4-c]pyridin-4-one, 1-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,5,6,7-tetrahydro-5-methyl- (9CI) (CA INDEX NAME)



RN 358733-25-2 CAPLUS

CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-[(4,5,6,7-tetrahydro-5-methyl-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]- (9CI) (CA INDEX NAME)




RN 358733-26-3 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-[(4,5,6,7-tetrahydro-5-methyl-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]- (9CI) (CA INDEX NAME)




09/191,199




RN 358733-27-4 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N,N-dimethyl-2-oxo-3-[(4,5,6,7-tetrahydro-5-methyl-4-oxo-2H-pyrrolo[3,4-c]pyridin-1-yl)methylene]- (9CI)  
(CA INDEX NAME)



RN 358733-28-5 CAPLUS


CN Pyrano[3,4-c]pyrrol-4(2H)-one, 1-[(1,2-dihydro-2-oxo-3H-pyrrolo[2,3-b]pyridin-3-ylidene)methyl]-6,7-dihydro- (9CI) (CA INDEX NAME)



09/191,199

L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2001 ACS  
AN 2001:472721 CAPLUS  
DN 135:76886  
TI Preparation of 4-substituted 7-azaindolin-2-ones and their use as protein kinase inhibitors  
IN Liang, Congxin; Sun, Li; Wei, Chung Chen; Tang, Peng Cho; McMhlon, Gerald; Hirth, Klaus Peter; Cui, Jingrong  
PA Sugen, Inc., USA  
SO PCT Int. Appl., 97 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001046196	A1	20010628	WO 2000-US34259	20001221
	W:				
					AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
	RW:				GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRAI	US 1999-171288	P	19991221		
OS	MARPAT 135:76886				
GI					



AB This invention relates to 4-substituted 7-azaindolin-2-ones I [R1 = H, Me; R2, R3 = H, halo, alkyl, alkoxy or R2R3 = methylindene or hetero ring; R4 = H, Me, CF3, etc.; X = bond, ethynyl, O, S, etc.; Y = ring; Z = N, CR6] and their use as protein kinase inhibitors. E.g., -[4-(1-benzyl-1H-indol-5-ylamino)-6-oxo-6,7-dihydropyrrolo[2,3-d]pyrimidin-5-ylidenemethyl]-4-methyl-1H-pyrrole-2-carboxylic acid (2-morpholin-4-ylethyl)amide hydrochloride was prepd. from 5-(4-chloro-6-oxo-6,7-dihydropyrrolo[2,3-d]pyrimidin-5-ylidenemethyl)-4-methyl-1H-pyrrole-2-carboxylic acid(2-morpholin-4-yl-ethyl)amide and 1-benzyl-1H-indol-5-ylamine.

IT **346599-64-2P**  
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 4-substituted 7-azaindolin-2-ones and their use as protein kinase inhibitors)


RN 346599-64-2 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 5-[[4-[(3-chloro-4-fluorophenyl)amino]-1,2-dihydro-2-oxo-3H-pyrrolo[2,3-b]pyridin-3-ylidene]methyl]-4-methyl-N-[2-(4-


09/191,199

morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




IT **346600-27-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of 4-substituted 7-azaindolin-2-ones and their use as protein  
kinase inhibitors)

RN 346600-27-9 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 5-[(4-chloro-1,2-dihydro-2-oxo-3H-pyrrolo[2,3-  
b]pyridin-3-ylidene)methyl]-4-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI)  
(CA INDEX NAME)



09/191,199

RE.CNT 4



RE

- (1) Cockerill, G; WO 9802438 A 1998 CAPLUS
- (2) Glaxo Group Ltd; WO 9921859 A 1999 CAPLUS
- (3) Longo, A; US 5719135 A 1998 CAPLUS
- (4) Upjohn Co; WO 9320078 A 1993 CAPLUS

09/191,199

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2001 ACS  
AN 2000:117197 CAPLUS  
DN 132:166123  
TI 3-Methylidenyl-2-indolinone modulators of protein kinase  
IN Tang, Peng Cho; Sun, Li; Miller, Todd Anthony; Liang, Congxin; Tran, Ngoc  
My; Nguyen, Anh Thi; Nematalla, Asaad  
PA Sugan, Inc., USA  
SO PCT Int. Appl., 347 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000008202	A2	20000217	WO 1999-US17845	19990804
	WO 2000008202	A3	20000518		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9954684	A1	20000228	AU 1999-54684	19990804
PRAI	US 1998-129256	A	19980804		
	US 1998-95470	P	19980805		
	US 1998-102178	P	19980928		
	US 1999-116107	P	19990115		
	WO 1999-US17845	W	19990804		
OS	MARPAT 132:166123				
GI					



AB The title compds. (I) [wherein A = C or N; Q = substituted Ph, pyrrolyl, or indolyl; R0 = H, alkyl, C(O)R19, or C(O)OR19; R1 = H, (un)substituted alkyl, alkoxy, halo, aryl, (CH2)nOC(O)R19, or C(O)NR19; R2 = H, (cyclo)alkyl, (hetero)aryl, heteroalicyclic, trihalomethyl, alkoxy, halo, sulfamido, C(O)OR19, C(O)R19, NHC(O)OR19, (un)substituted amino, etc.; R3 = H, alkyl, trihalomethyl, alkoxy, aryl(oxy), heteroaryl, heteroalicyclic, OH, halo, sulfamido, C(O)R19, (un)substituted amino, etc.; R4 = H, alkyl, alkoxy, or halo; R19 = H, (cyclo)alkyl, alkenyl, alkynyl, or aryl; n = 1-4] were prepd. as modulators of the activity of receptor tyrosine kinases (RTKs), non-receptor protein tyrosine kinases (CTKs), and serine/threonine protein kinases (STKs). Examples include over 200 syntheses and data from seventeen bioassays. For instance, II was prepd. by a 3-step sequence involving: (1) cyclization and redn. of 2,4-dinitrophenylacetic acid with SnCl2.2H2O in EtOH to form 6-amino-2-oxindole, (2) amidation with AcCl in CH2Cl2, and (3) condensation of the amide with 3,5-diisopropyl-4-methoxybenzaldehyde. II was tested for HER-2 kinase activity (IC50 = 6.4 .mu.M), cellular proliferation activity as measured by the incorporation of bromodeoxyuridine (BrdU) driven by HER-2 (IC50 = 9.1 .mu.M) or EGF (IC50 = 11 .mu.M), and antitumor activity as measured by growth of SKOV3 ovarian carcinoma cells (IC50 = 2.6 .mu.M) or A431 human epidermoid carcinoma cells (IC50 = 2.2 .mu.M). The invention compds. are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer, diabetes, hepatic cirrhosis, cardiovascular disease, and immunol. disease.


IT **258831-03-7P**

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. of 3-methylidenyl-2-indolinones as protein kinase modulators for the prevention and treatment of cancer, diabetes, hepatic cirrhosis, cardiovascular disease, and immunol. disease)

RN 258831-03-7 CAPLUS


CN 1H-Indole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-pyrrolo[2,3-b]pyridin-3-ylidene)methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



09/191,199

L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2001 ACS  
AN 1999:297422 CAPLUS  
DN 130:325139  
TI Preparation of arylmethylideneazaoxindoles as protein kinase inhibitors.  
IN Cheung, Mui; Glennon, Kimberly Caroline; Lackey, Karen Elizabeth; Peel, Michael Robert  
PA Glaxo Group Limited, UK  
SO PCT Int. Appl., 135 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9921859	A1	19990506	WO 1998-EP6357	19981008
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9911510	A1	19990517	AU 1999-11510	19981008
PRAI	GB 1997-21437		19971010		
	WO 1998-EP6357		19981008		
OS	MARPAT 130:325139				
GI					



AB Title compds. [I; R1 = (substituted) Het, aryl, biaryl; R2-R4 = H, het, fused Het, aryl, alipharyl, cyano, NO2, halo, OR5, SR5, SOR5, NR5R7, COR5, CO2R5, NR5COR5, CONR5R7, etc.; R5 = H, halo, (substituted) Het, aryl, alipharyl, etc.; R7 = H, R5; Het = (R5 -substituted) acridinyl, benzimidazolyl, benzofuryl, carbazolyl, dithianyl, furyl, imidazolyl, morpholinyl, naphthyridinyl, oxadiazinyl, oxathiazolyl, pyrazolyl, pyridazinyl, quinoxalinyl, tetrazinyl, thiomorpholinyl, thiopyranyl, etc.], were prepd. Thus, 5-bromo-7-azaoxindole (prepn. given), 1-(3,5-dichlorophenyl)pyrrole-2-carboxaldehyde, and 4-methylmorpholine were refluxed in PhMe for 6 h to give 64% 5-bromo-3-[1-(3,5-dichlorophenyl)-1H-pyrrol-2-ylmethylidene]-1,3-dihydropyrrolo[2,3-b]pyridin-2-one. Several I inhibited raf kinase with IC50 < 1 .mu.M.

IT **223645-86-1P 223645-93-0P 223645-94-1P**  
**223645-99-6P**


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of arylmethylideneazaoxindoles as protein kinase inhibitors)

RN 223645-86-1 CAPLUS

09/191,199


CN 2H-Pyrrolo[2,3-b]pyridin-2-one, 5-bromo-3-[[1-(3,5-dichlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 223645-93-0 CAPLUS


CN 2H-Pyrrolo[2,3-b]pyridin-2-one, 5-bromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 223645-94-1 CAPLUS

CN 2H-Pyrrolo[2,3-b]pyridin-2-one, 3-(2-furanylmethylene)-1,3-dihydro-5-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 223645-99-6 CAPLUS

CN 2H-Pyrrolo[2,3-b]pyridin-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-5-(2-furanyl)-1,3-dihydro- (9CI) (CA INDEX NAME)



RE.CNT 1

RE

(1) Pharmacia; WO 9616964 A 1996 CAPLUS





Creation date: 02-05-2004  
Indexing Officer: KHALL - KIM HALL  
Team: OIPEBackFileIndexing  
Dossier: 09191199

Legal Date: 10-19-2001

No.	Doccode	Number of pages
1	CTNF	21
2	892	1
3	1449	1
4	1449	1

Total number of pages: 24

Remarks:

Order of re-scan issued on .....